T-DM1 Benefits'Striking' in HER2+ Early Breast Cancer T-DM1 Benefits'Striking' in HER2+ Early Breast Cancer

Lidia Schapira provides her perspective on a recent study of trastuzumab emtansine in residual invasive HER2+ breast cancer.Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Viewpoint Source Type: news

Related Links:

Condition:   Breast Cancer Intervention:   Diagnostic Test: SPECT Sponsors:   Tomsk National Research Medical Center of the Russian Academy of Sciences;   KTH Royal Institute of Technology;   Uppsala University Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HER2-Negative Breast Cancer Intervention:   Drug: Pembrolizumab Sponsors:   University of Malaya;   Merck Sharp & Dohme (MSD);   National University Hospital, Singapore;   Clinical Research Malaysia Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HER2-positive Early Breast Cancer Interventions:   Drug: SIBP-01;   Drug: Herceptin;   Drug: Docetaxel;   Drug: Carboplatin Sponsors:   Shanghai Institute Of Biological Products;   Fudan University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HER2-Negative Breast Cancer Intervention:   Drug: Pembrolizumab Sponsors:   University of Malaya;   Merck Sharp & Dohme (MSD);   National University Hospital, Singapore;   Clinical Research Malaysia Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HER2-positive Early Breast Cancer Interventions:   Drug: SIBP-01;   Drug: Herceptin;   Drug: Docetaxel;   Drug: Carboplatin Sponsors:   Shanghai Institute Of Biological Products;   Fudan University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Metastatic Breast Cancer Interventions:   Drug: Abemaciclib;   Drug: Nonsteroidal Aromatase Inhibitor (NSAI) Sponsor:   Eli Lilly and Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Breast Cancer Interventions:   Drug: Pembrolizumab;   Drug: Trastuzumab Biosimilar ABP 980;   Drug: Pertuzumab Sponsors:   West German Study Group;   Merck Sharp & Dohme Corp.;   Amgen;   NanoString Technologies, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Metastatic Breast Cancer Interventions:   Drug: Abemaciclib;   Drug: Nonsteroidal Aromatase Inhibitor (NSAI) Sponsor:   Eli Lilly and Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Breast Cancer Interventions:   Drug: Pembrolizumab;   Drug: Trastuzumab Biosimilar ABP 980;   Drug: Pertuzumab Sponsors:   West German Study Group;   Merck Sharp & Dohme Corp.;   Amgen;   NanoString Technologies, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Metastatic Breast Cancer Interventions:   Drug: Abemaciclib;   Drug: Nonsteroidal Aromatase Inhibitor (NSAI) Sponsor:   Eli Lilly and Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Health | Hematology | HER2 | Herceptin | Study